Abstract
ABSTRACTBackground: Methicillin-resistant Staphylococcus aureus (MRSA) is an organism causing significant mortality and morbidity with nosocomial infections. Ceftaroline is a new cephalosporin antibiotic that has activity against MRSA. In the USA, this antibiotic has not been approved for use in pneumonia caused by MRSA.Objectives: To review the use of ceftaroline in MRSA pneumonia in a US hospital and evaluate its clinical success.Methods: A retrospective study was conducted in an urban community hospital assessing the use of ceftaroline for MRSA pneumonia.Results: The clinical success was comparable to the currently approved treatment for MRSA pneumonia.Conclusion: The results of our study showed a favorable result for the treatment of MRSA pneumonia. Well-designed studies need to be performed for further validation of these results.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
